secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indivior Pharmaceuticals, Inc. (INDV)
CIK:        0001625297
Form:       8-K
Filed at:   2025-08-22T23:59:59+00:00
Accession:  0001625297-25-000056
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indivior PLC enters new employment agreements with CFO Ryan Preblick; no changes to compensation or role
--------------------------------------------------------------------------------

- New employment agreement for CFO Ryan Preblick, effective Jan 1, 2025, aligns with current U.S. executive forms.
- No changes to compensation, responsibilities, or title from prior 2020 agreement.
- Annual base salary remains $558,819; cash bonus target at 60% of base salary (max 120%).
- LTIP annual award anticipated at 400% of base salary, subject to Compensation Committee discretion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625297/000162529725000056/0001625297-25-000056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625297/000162529725000056/indv-20250820.htm
  HTML page:      https://secwatch.observer/filing/0001625297-25-000056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer